‘Major bottleneck’ still limits Alzheimer’s drug

By
dementianews
-
Biogen CEO: 'Major bottleneck' still limits Alzheimer's drug
This image provided by Biogen on Monday, June 7, 2021 shows a vial and packaging for the drug Aduhelm. The first new Alzheimer’s treatment in more than 20 years was hailed as a breakthrough when regulators approved it in June 2021, but its rollout has been slowed by questions about its price and how well it works. Credit: Biogen via AP, File

A new Alzheimer’s drug from Biogen brought in only $300,000 in sales during its first full quarter on the market, extending a slow debut complicated by coverage questions and doctor concerns.

The infused drug, hailed as a potential breakthrough treatment for a fatal disease, has encountered a health care system that “remains…

Read more…

RELATED ARTICLESMORE FROM AUTHOR